A secret field that summons lightning. A massive spiral that disappears into a salt lake. A celestial observatory carved into a volcano. Meet the wild—and sometimes explosive—world of land art, where artists craft masterpieces with dynamite and bulldozers. In our Season 2 premiere, guest Dylan Thuras, cofounder of Atlas Obscura, takes us off road and into the minds of the artists who literally reshaped parts of the Southwest. These works aren’t meant to be easy to reach—or to explain—but they just might change how you see the world. Land art you’ll visit in this episode: - Double Negative and City by Michael Heizer (Garden Valley, Nevada) - Spiral Jetty by Robert Smithson (Great Salt Lake, Utah) - Sun Tunnels by Nancy Holt (Great Basin Desert, Utah) - Lightning Field by Walter De Maria (Catron County, New Mexico) - Roden Crater by James Turrell (Painted Desert, Arizona) Via Podcast is a production of AAA Mountain West Group.…
Player FM - Internet Radio Done Right
Checked 10d ago
Lisätty thirty-eight viikkoa sitten
Sisällön tarjoaa RTW Investments, LP, RTW Investments, and LP. RTW Investments, LP, RTW Investments, and LP tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
))
Daily Deals
Kuuntelemisen arvoisia podcasteja
SPONSOROITU
The RTW Podcast
Merkitse kaikki (ei-)toistetut ...
Manage series 3594249
Sisällön tarjoaa RTW Investments, LP, RTW Investments, and LP. RTW Investments, LP, RTW Investments, and LP tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
We’re witnessing a healthcare revolution, as medical and science innovations transform the lives of millions. Join as we speak to bright scientific minds, inspiring company founders and healthcare champions that are driving this exciting period of scientific discovery.
Subscribe to catch each episode as it goes live.
The content of this podcast does not constitute investment advice, an offer to provide investment advisory services, or an offer to sell or solicitation of an offer to buy an interest in any investment fund.
6 jaksoa
Jaa
Merkitse kaikki (ei-)toistetut ...
Manage series 3594249
Sisällön tarjoaa RTW Investments, LP, RTW Investments, and LP. RTW Investments, LP, RTW Investments, and LP tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
We’re witnessing a healthcare revolution, as medical and science innovations transform the lives of millions. Join as we speak to bright scientific minds, inspiring company founders and healthcare champions that are driving this exciting period of scientific discovery.
Subscribe to catch each episode as it goes live.
The content of this podcast does not constitute investment advice, an offer to provide investment advisory services, or an offer to sell or solicitation of an offer to buy an interest in any investment fund.
6 jaksoa
Kaikki jaksot
×
Connor Williams was shocked when the data came back for GH001. What could this mean for the future of treatment-resistant depression? Listen to his exclusive interview with Dr. Valcheva, the CEO of GH Research, to find out. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Featuring: Dr. Velichka (Villy) Valcheva MD, CEO of GH Research moderated by Connor Williams, Senior Research Analyst at RTW Investments. Don't forget to listen to part 1 of Connor’s discussion on treatment resistant depression and psychedelics with Stephanie Sirota, Managing Partner and Chief Business Officer at RTW Investments. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify , Apple Podcasts , Amazon Music , and most other podcast platforms. CHAPTERS 00:00 – Introduction 01:09 – About GH Research 04:20 – Becoming CEO of GH Research 06:27 – The difference between GH001 and other psychedelics 11:37 – The difficulties of developing a scheduled substance 12:27 – Dealing with the stigma of psychedelics 15:31 – What else can GH001 treat? 17:26 – The future of GH Research 20:53 – Outro and Disclaimer DISCLAIMER This interview was given by Dr. Velichka (Villy) Valcheva MD, CEO of GH Research, and moderated by Connor Williams, Senior Research Analyst at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.…
If you’re dismissing psychedelics in pharma, think again. Stephanie Sirota and Connor Williams discuss overcoming stigma and regulatory challenges, and the results of a recent clinical trial that could signal a new era for mental health care. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Featuring: Connor Williams, Senior Researcher at RTW Investments, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments. Stay tuned for a deep dive into psychedelics with the CEO of GH Research, Dr. Velichka (Villy) Valcheva, moderated by Connor Williams. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify , Apple Podcasts , Amazon Music , and most other podcast platforms. CHAPTERS 00:00 - Introduction 00:21 - The development of psychiatric drugs 03:29 - Treatment resistant patients in the U.S. and the international market 05:50 - The need for new depression treatment drugs 08:05 - The rise of psychedelics & the impact of regulations and policies 13:58 - New areas of study in psychedelics 14:43- The valuation of psychedelics and what it means for investors 17:53 - Discovering GH Research and its novel approach to TRD 22:11 - Outro and disclaimer DISCLAIMER This interview was given by Connor Williams, Senior Researcher at RTW Investments, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.…
Dr. Rekha Kumar, Chief Medical Officer at Found, and Stephanie Sirota explore Rekha’s rise from academia, and her passion for obesity medicine. As new weight management therapies emerge, Rekha emphasizes the importance of lifestyle changes to maximize their potential. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Featuring: Dr. Rekha B. Kumar, moderated by Stephanie Sirota. Don't forget to listen to part one of Stephanie's discussion on GLP-1s with Rod Wong, Managing Partner and Chief Investment Officer at RTW. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify , Apple Podcasts , Amazon Music , and most other podcast platforms. CHAPTERS 00:00 - Introduction 00:38 - Dr. Rekha Kumar’s journey into obesity medicine 04:18 - Establishing Found and treating obesity patients 08:56 - Telehealth and its impact on obesity treatment 12:59 - Understanding how GLP-1s work 17:18 - Obesity as an area of study in medicine 18:47 - Thoughts on the future of obesity medicine 20:02 - Outro DISCLAIMER This interview was given by Dr. Rekha B. Kumar, endocrinologist, obesity medicine specialist, and Chief Medical Officer at Found, and moderated by Stephanie Sirota, Chief Business Officer and Partner at RTW Investments. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.…
Rod Wong and Stephanie Sirota delve into the transformative potential of GLP-1 drugs, focusing on their impact on obesity and related diseases. Rod shares his insights into the next generation of obesity therapies and the opportunities they present for innovation and investment in the biotech sector. PODCAST TEAM Producer: Devon Leaver Editor: Dominique Guerra Featuring: Rod Wong, moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments. Stay tuned for part two of our discussion on GLP-1s where we welcome Dr. Rekha B. Kumar to the studio at RTW HQ. FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify , Apple Podcasts , Amazon Music , and most other podcast platforms. CHAPTERS 00:00 - Introductions 00:39 - Understanding the importance of GLP-1s 02:27 - GLPs in the cycle of obesity drug development 05:13 - Public and private company interest in obesity drugs 06:58 - Cost benefits of GLP-1s and their Impact on the healthcare system 10:30 - The value of GLP-1s in the investor space 12:36 - GLP-1s in the international market 16:12 - The expansion of large companies into GLP-1s 18:35 - Thoughts on recent investments and the potential of Kailera Therapeutics 19:52 - Outro and disclaimer DISCLAIMER This interview was given by Rod Wong, Managing Partner and Chief Investment Officer of RTW Investments, and moderated by Stephanie Sirota, Chief Business Officer, and Partner at RTW Investments. Statements reflect RTW’s views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results.…
Sarah Boyce from Avidity Biosciences and Piratip Pratumsuwan from RTW Investments explore the strategic decisions and innovations that have driven Avidity's success. They cover her approach to overcoming the challenges of scaling a biotech company, the impact of Avidity’s groundbreaking work on treating rare genetic disorders, and Sarah’s vision for the future of RNA-based therapies. PODCAST TEAM Producer: Devon Leaver Technical Director: Joseph Sebring Editor: Dominique Guerra Featuring: Sarah Boyce , President and CEO of Avidity Biosciences , and Piratip Pratumsuwan , Managing Director; Research Analyst at RTW Investments . FOLLOW US Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights. To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify , Apple Podcasts , Amazon Music , and most other podcast platforms. CHAPTERS 00:00 - Introducing Sarah Boyce and Piratip Pratumsuwan 01:09 - Avidity Biosciences: Pioneering RNA therapeutics 02:20 - Joining Avidity: A bold decision 03:55 - Navigating challenges and embracing opportunities 12:00 - FSHD and Fortitude 18:21 - Looking Ahead: The future of RNA therapeutics 20:10 - Championing women in biotechnology 21:43 - Credits and disclaimer DISCLAIMER This interview and testimonial was given by Sarah Boyce , CEO of Avidity Biosciences, a company in which RTW has made an equity investment on behalf of its managed funds. No compensation was provided to Ms. Boyce.…
Mark McKenna from Prometheus Biosciences and Josh Kennedy-Smith from RTW Investments tell us about the white-knuckle ride that is building a pharmaceutical start-up, their passion for providing better care solutions for patients, the recent deal with Merck and the power of a strong partnership with your investor. Host: Josh Baldwin, RTW Investments Featuring: Mark McKenna, CEO of Prometheus Biosciences and Josh Kennedy-Smith, Managing Director; Research Analyst of RTW Investments…
Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.
Daily Deals
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
))
